EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Advances in radiopharmaceuticals for cancer radiotheranostics: CCK2R targeting as a paradigm for translational innovation

Jing Li, Xuejun Wen, Rebeka Rita Reszegi, Hemavarshini Kamalrhaj, Wolfgang J Parak, Xiaoyuan Chen iD, Jingjing Zhang

Cancer Communications · 2025

DOI: 10.1002/cac2.70063 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Communications, 2025. Verfasst von Jing Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. Hauptthemen laut MEDLINE: Radiopharmaceuticals, Neoplasms, Receptor, Cholecystokinin B. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 135 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National University of Singapore, National Medical Research Council, Singapore Ministry of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radiopharmaceuticals are reshaping the landscape of cancer therapy, offering a unique theranostic advantage that is becoming increasingly central to precision medicine. By labeling the same molecular scaffold with different radionuclides, these agents enable seamless integration of diagnostic imaging and targeted therapy. Clinical breakthroughs with somatostatin receptor subtype 2 (SSTR2)‐ and prostate‐specific membrane antigen (PSMA)‐targeted radiopharmaceuticals have significantly enhanced both tumor visualization and therapeutic efficacy, establishing new benchmarks in oncology. Ongoing research is exploring novel molecular targets such as cholecystokinin‐2 receptor (CCK2R), fibroblast activation protein (FAP), and C‐X‐C chemokine receptor type 4 (CXCR4). In parallel, there is growing interest in utilizing alternative radionuclides, including alpha‐particle emitters and Auger electron emitters, beyond the commonly used beta‐emitters, to improve therapeutic outcomes. Simultaneously, advances in ligand and linker design are being leveraged to optimize in vivo pharmacokinetics and tissue distribution. Among the emerging targets, CCK2R has attracted notable attention due to its overexpression in multiple malignancies. Research efforts have focused on improving ligand stability, receptor‐binding affinity, and tumor retention, while also exploring strategies to enhance CCK2R expression on cancer cells. This review offers a comprehensive overview of the current landscape in cancer radiotheranostics, exploring the role of CCK2R in cancer biology and summarizing the latest advancements in the development of CCK2R‐targeted radiopharmaceuticals. Using these advancements as a case study, we systematically examine key aspects of next‐generation radiopharmaceutical design, from target selection and ligand engineering to pharmacokinetic optimization and clinical translation, providing a multidimensional framework for future innovation in cancer radiotheranostics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiopharmaceuticalsNeoplasmsReceptor, Cholecystokinin BHumansAnimalsTheranostic NanomedicineTranslational Research, BiomedicalMolecular Targeted Therapy

Stichwörter der Autor:innen

CCK2Rcancer theranosticsmolecular targetsradiopharmaceuticalsradiotheranostics

Substanzen

RadiopharmaceuticalsReceptor, Cholecystokinin B

Autor:innen und Institutionen

  • Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Theranostics Centre of Excellence, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Institute for Nanostructure and Solid State Physics, University of Hamburg, Hamburg, Germany.
  • Hamburg Centre for Ultrafast Imaging, University of Hamburg, Hamburg, Germany.
  • Nanomedicine Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
  • Clinical Imaging Research Centre, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.

ORCID-Profile: Xiaoyuan Chen

Förderung

  • National University of Singapore
  • National Medical Research Council
  • Singapore Ministry of Education
  • NUS School of Medicine Nanomedicine Translational Research Programme

Zitieren

APA

Li, J., Wen, X., Reszegi, R. R., Kamalrhaj, H., Parak, W. J., Chen, X., & Zhang, J. (2025). Advances in radiopharmaceuticals for cancer radiotheranostics: CCK2R targeting as a paradigm for translational innovation. Cancer Communications. https://doi.org/10.1002/cac2.70063

Vancouver

Li J, Wen X, Reszegi RR, Kamalrhaj H, Parak WJ, Chen X, et al. Advances in radiopharmaceuticals for cancer radiotheranostics: CCK2R targeting as a paradigm for translational innovation. Cancer Communications. 2025. doi:10.1002/cac2.70063

BibTeX
@article{Li2025,
  author = {Li, Jing and Wen, Xuejun and Reszegi, Rebeka Rita and Kamalrhaj, Hemavarshini and Parak, Wolfgang J and Chen, Xiaoyuan and Zhang, Jingjing},
  title = {Advances in radiopharmaceuticals for cancer radiotheranostics: CCK2R targeting as a paradigm for translational innovation},
  journal = {Cancer Communications},
  year = {2025},
  doi = {10.1002/cac2.70063}
}
Kostenlos starten →